Wpd Pharmaceuticals Completed The Acquisition Of Two Pancreatic Cancer Drug Candidates

Wpd Pharmaceuticals Completed The Acquisition Of Two Pancreatic Cancer Drug Candidates

By, Admin 3 February 2020

Wpd Pharmaceuticals Inc., A Clinical Stage Pharmaceutical Company, Provides This Update On The Completed Acquisition Of Exclusive Sublicenses For Two Drug Candidates From Moleculin Biotech, Inc. (Nasdaq: Mbrx) A Leading Global Pharmaceuticals Company Focused On The Treatment Of Highly Resistant Cancers. The Territory Covered By The Patents Includes 30 Countries In Europe And Asia, Including Russia.The Licensed Drug Candidates, Wp1122 And Wp1732, Are Both Considered Promising Potential Therapies For Treating Pancreatic Cancer, Among Other Highly Resistant Tumors. Wp1732 Appears Capable Of A Disproportionately High Accumulation In The Pancreas, Making It A Promising Candidate For Treating Pancreatic Cancer. Wp1122 Is Capable Of Inhibiting Glycolysis, A Process By Which Cells Convert Glucose Into Energy And One On Which Many Tumor Cells Are Known To Be Much More Dependent For Their Survival Than Normal Cells. In Particular, Pancreatic Cancer Is Known To Be Highly Dependent On Glycolysis.The Incidence Of And Number Of Deaths Caused By Pancreatic Cancer Have Been Gradually Rising, Even As The Incidence And Mortality Of Other Common Cancers Have Been Declining. Removal Of The Pancreatic Cancer Tumor Is Currently The Only Chance Of Cure. Unfortunately, 80% To 85% Of Patients Diagnosed With Pancreatic Cancer Are At An Advanced Stage And The Tumor Has Overtaken The Pancreas And Even Surrounding Tissues. Furthermore, Pancreatic Cancer Responds Poorly To Most Chemotherapeutic Agents.Mariusz Olejniczak, Ceo Of Wpd Commented, â‚

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!